Abstracts tagged "proteomics"

Abstract Number: 0962 • ACR Convergence 2023
Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma
Irene Choi¹, Courtney Yu², Francesco Boin¹, Elizabeth Volkmann³, Stephanie Stanford² and Nunzio Bottini⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴University of California, San Francisco, CA
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune and rheumatic disease characterized by varying levels of tissue fibrosis in the skin and other internal organs. It…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Ayesha Butt¹, Rolando Garcia Milian¹, George Goshua¹, Sean Gu¹, Eugenia Chock², Valentina Restrepo¹, John Hwa¹, Hyung Chun¹, H Michael Belmont³, Kello Nina⁴, D. Ware Branch⁵, Michelle Petri⁶, Jason Knight⁷, Rohan Willis⁸, Maria Laura Bertolaccini⁹, Doruk Erkan¹⁰, Alfred lee¹, Anish Sharda¹ and Alexander Pine¹¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Greenwich, CT, ³NYU School of Medicine, New York, NY, ⁴Northwell Health, Brooklyn, NY, ⁵University of Utah, Salt Lake City, UT, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Texas Medical Branch, Galveston, TX, ⁹King's College London, London, United Kingdom, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹VA Connecticut/Yale School of Medicine, West Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Stephanie Finzel¹, Andrea Grioni², Benjamin A Fisher³, Athena S Papas⁴, Alexandre Avrameas², Danny Tuckwell², Jonas Zierer², Celine Rauld², Valeria De Luca², Enrico Ferrero², Andre Nogueira da Costa², Rainer Hillenbrand², Isabelle Isnardi² and Wolfgang Hueber², ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³University of Birmingham, Birmingham, United Kingdom, ⁴Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 1637 • ACR Convergence 2023
IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity
Helena Achten¹, Liselotte Deroo², Kristel De Boeck³, Matthias Jarlborg¹, Tine Decruy¹, Joke Deprez¹, Emilie Dumas¹, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Ghent, Belgium, ²Ghent University, Gent, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵University Hospital Ghent, Ghent, Belgium
Background/Purpose: Loss of galactose and sialic acid structures attached to the IgG-Fc-fragment switches the antibody effector function from anti-inflammatory to pro-inflammatory1. This study investigated the…
Abstract Number: 0020 • ACR Convergence 2023
The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups
José Miguel Sequí-Sabater¹, Carlos Perez-Sanchez², Clarissa Meoni³, Tomás Cerdó-Ráez⁴, Maria del Carmen Abalos-Aguilera⁵, Desiree Ruiz Vilchez⁵, Francisco Cepas⁴, Nuria Barbarroja⁶, Alejandro Escudero⁷, Mª Angeles Aguirre⁸, Chary Lopez-Pedrera⁹ and Lorenzo Beretta¹⁰, ¹Agencia Valenciana de Salut/ Hospital Universitari de la Ribera/ Unitat de Reumatología, Gandía, Spain, ²IMIBIC, Córdoba, Spain, ³Ospedale Policlinico di Milano, Milan, Italy, ⁴Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁶University of Cordoba, Córdoba, Spain, ⁷SAS, Córdoba, Spain, ⁸Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁹IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹⁰Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterised by glandular involvement of the eye and salivary glands, leading to xerostomia and xerophthalmia. In…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
Abstract Number: 0023 • ACR Convergence 2023
Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis
Avital Baniel¹, Mariko Ogawa-Momohara², Muhammad Bashir³, Rachita Pandya¹, Julianne Kleitsch¹, Felix Chin⁴, Ming-Lin Liu¹ and Victoria P. Werth⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) have been implicated in autoimmune disease pathogenesis. Plasma-derived DNA containing EVs have been shown to induce STING-mediated proinflammatory responses in dermatomyositis…
Abstract Number: 1698 • ACR Convergence 2023
High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis
Huihua Ding, Yiwei Shen, Min Dai and Nan Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…
Abstract Number: 0116 • ACR Convergence 2023
Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
Chary Lopez-Pedrera¹, Beatriz Vellón², Mª Angeles Aguirre³, Ismael Sanchez-Pareja², Laura Muñoz-Barrera², Tomás Cerdó², Pedro Segui², Christian Merlo-Ruiz², Desiree Ruiz-Vilchez², Maria del Carmen Abalos-Aguilera⁴, Nuria Barbarroja⁵, Alejandro Escudero Contreras⁶, Rafaela Ortega-Castro² and Carlos Perez-Sanchez⁷, ¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁵University of Cordoba, Córdoba, Spain, ⁶Reina Sofia University Hospital, Córdoba, Spain, ⁷IMIBIC, Córdoba, Spain
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by a hypercoagulable state, leading to arterial, venous, or microvascular thrombosis and accelerated atherosclerosis. Timely diagnosis…
Abstract Number: 1765 • ACR Convergence 2023
Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
Jeba Maisha, Xiaobo Meng, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Cigarette smoking (CS) is a major environmental risk factor for the development of Rheumatoid Arthritis (RA), and is associated with the development of RA…
Abstract Number: 0427 • ACR Convergence 2023
Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells
Laura Muñoz-Barrera¹, Carlos Perez-Sanchez², Laura Romero-Zurita¹, Rafaela Ortega Castro³, Jerusalem Calvo⁴, Pilar Font Ugalde¹, Marta Rojas⁵, Ismael Sanchez-Pareja¹, Maria del Carmen Abalos-Aguilera⁶, Desiree Ruiz-Vilchez¹, Christian Merlo-Ruiz¹, Mª Angeles Aguirre⁷, Nuria Barbarroja⁸, Tomás Cerdó¹, Eduardo Collantes Estévez⁹, Marta Alarcon-Riquelme¹⁰, Alejandro Escudero Contreras⁴ and Chary Lopez-Pedrera¹¹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²IMIBIC, Córdoba, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain, ⁵Hospital Universitario Reina Sofía, Cordoba, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁷Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁸University of Cordoba, Córdoba, Spain, ⁹Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹⁰Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, a significant proportion of patients (10-30%) fail to respond to current medications, including biologics. A better characterization…
Abstract Number: 1780 • ACR Convergence 2023
Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova², Lucia Ondrejcakova³, Vladimir Cervenak⁴, Monika Gregova⁵, Sarka Forejtova⁵, Jana Horinkova¹, Jindriska Gatterova⁶, Michal Tomcik⁷, Jiri Vencovsky⁷, Karel Pavelka⁸ and Ladislav Senolt⁹, ¹Institute of Rheumatology, Prague, Czech Republic, ²First faculty of medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Department of Medical Imaging, St Anne's University Hospital, and Faculty of Medicine, Masaryk University, Brno, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ⁶Rheumatology Institute, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Axial spondyloarthritis (AxSpA) is a frequent inflammatory disease with a significant impact on a patient's quality of life. Therefore, early diagnosis and recognition of…
Abstract Number: 0735 • ACR Convergence 2023
Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis
Jun Inamo¹, Joshua Keegan², Alec Griffith², Tusharkanti Ghosh³, Alice Horisberger², Kaitlyn Howard², John Pulford², Ekaterina Murzin², Brandon Hancock², The Accelerating Medicines Partnership SLE/RA⁴, Marie Feser⁴, Jill Norri⁵, Anna Helena Jonsson⁶, Ye Cao⁷, William Apruzzese⁸, S. Louis Bridges⁹, Vivian Bykerk¹⁰, Susan Goodman⁹, Laura Donlin⁹, Gary S Firestein¹¹, Harris Perlman¹², Joan Bathon¹³, Laura Hughes¹⁴, Darren Tabechian¹⁵, Andrew Filer¹⁶, Costantino Pitzalis¹⁷, Jennifer Anolik¹⁵, Larry Moreland¹⁸, Joel Guthridge¹⁹, Judith James¹⁹, Michael Brenner², Soumya Raychaudhuri⁶, Jeffrey Sparks²⁰, Jennifer Seifert²¹, Michael Holer⁴, Kevin Deane⁴, James Lederer², Deepak Rao⁶ and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Colorado School of Public Health, Denver, CO, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Department of Medicine, University of California San Diego, La Jolla, CA, ¹²Northwestern University, Chicago, IL, ¹³Columbia University, New York, NY, ¹⁴University of Alabama at Birmingham Medicine, Birmingham, AL, ¹⁵University of Rochester Medical Center, Rochester, NY, ¹⁶University of Birmingham, Birmingham, United Kingdom, ¹⁷Queen Mary University of London, London, United Kingdom, ¹⁸University of Colorado, Denver, CO, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²¹The Accelerating Medicines Partnership RA/SLE Network, ²²University of Colorado, Aurora, CO

Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been used to investigate established RA heterogeneity…
Abstract Number: 1795 • ACR Convergence 2023
Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
Chiara Pastrello¹, Darshini Ganatra², Max Kotlyar¹, Nikita Looby², Quan Li³, Lihi Eder⁴, Dafna Gladman⁵, Proton Rahman³, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with cutaneous psoriasis. Due to the lack of clinically useful diagnostic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.